Asset
Pralsetinib
Rigel Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07704658 | phase4 | recruiting | 2026-03-04 | 2027-07-30 | Rigel Pharmaceuticals | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 213721 | NDA | RIGEL PHARMACEUTICALS INC |
Marketed products (1)
- GAVRETO